CSL Behring, a global biotherapeutics leader, has inaugurated its regional headquarters at Dubai Science Park (DSP), a holistic science-focused business community dedicated to the development of the local healthcare sector.

The opening of the new office will strengthen the company’s presence in the Middle East and Africa (MEA) region, ultimately leading to better patient care and increased awareness of treatment options for critical medical conditions.

The inauguration drew the participation of Markus Staempfli, vice president and general manager for Intercontinental Commercial Operations at CSL Behring, Mohammed Haggag, general manager of CSL Behring MEA, and Marwan Abdulaziz Janahi, managing director of DSP and chairing member of the Pharmaceuticals and Medical Equipment Taskforce of the Dubai Industrial Strategy 2030.

Biotherapeutics is one of the fastest-growing segments of the pharmaceutical industry. Its annual growth is estimated at more than 10 per cent, compared to conventional pharmaceuticals at seven percent. The UAE’s positive investment climate and its attractiveness as a hub for pharma and healthcare activities has encouraged multiple international companies to set up locally, especially in niche industries.
CSL Behring is a leader in the $24 billion plasma market. The company’s commitment to innovation is reflected in its development of breakthrough therapies to reduce the risk of early recurrent cardiovascular events, improve the outcomes of organ transplants, and treat sickle cell disease, β-thalassemia and autoimmune diseases.

Marwan Abdulaziz Janahi said: “As a keen enabler of world-class healthcare– one of the national priorities of the UAE Vision 2021, DSP is proud to host pioneers in the field such as CSL Behring. The inauguration of the company’s regional headquarters aligns with our strategy of attracting internationally recognised pharma and healthcare players. With its collaborative environment and wide range of business offerings, DSP can support CSL Behring in achieving its growth objectives and bringing state-of-the-art treatments to the residents of the GCC region.”

Markus Staempfli said: “The opening of our new office in DSP demonstrates our growth and the increasing demand for our life-saving products. We remain committed to delivering on our promise to patients, and will continue to deepen our footprint in the MEA region to reach more people with medicines that can help transform their lives.”

With global operational headquarters based in Pennsylvania, USA, CSL Behring owns one of the world’s largest plasma collection networks and operates six research facilities around the world. As part of its growth strategy, the company has placed a strong emphasis on expansion in emerging markets in order to better serve patients’ needs through leveraging the latest technologies to develop and deliver innovative therapies for rare and life-threatening diseases. CSL Behring’s foray into the MEA region is expected to create employment opportunities for local talent.

Currently home to over 350 business partners, Dubai Science Park provides a conducive environment for science companies to setup, grow and flourish. The business community aims to contribute to consolidating Dubai’s position as a preferred destination for local and international companies within the science sector. – TradeArabia News Service